The hypothesis that amyloid- (A) peptides are the primary cause of Alzheimer's disease (AD) remains the best supported theory of AD pathogenesis. Yet, many observations are inconsistent with the hypothesis. A peptides are generated when amyloid precursor protein (APP) is cleaved by presenilins, a process that also produces APP intracellular domain (AICD). We previously generated AICDoverexpressing transgenic mice that showed abnormal activation of GSK-3, a pathological feature of AD. We now report that these mice exhibit additional AD-like characteristics, including hyperphosphorylation and aggregation of tau, neurodegeneration and working memory deficits that are prevented by treatment with lithium, a GSK-3 inhibitor. Consistent with its potential role in AD pathogenesis, we find AICD levels to be elevated in brains from AD patients. The in vivo findings that AICD can contribute to AD pathology independently of A have important therapeutic implications and may explain some observations that are discordant with the amyloid hypothesis.amyloid precursor protein ͉ neurodegeneration ͉ tau hyperphosphorylation A lzheimer's disease (AD) is a neurodegenerative disorder that begins with deficits in short-term memory and culminates in total loss of cognition and executive functions. Neuropathologically, the disease is characterized by the presence of extracellular plaques enriched in amyloid-beta (A) peptides and intracellular neurofibrillary tangles containing hyperphosphorylated tau protein (1, 2). The A peptides are produced by the proteolytic processing of amyloid precursor protein (APP) (3, 4), which is cleaved by 'secretases' to produce multiple fragments. According to the amyloid hypothesis, A peptides are the primary causative agents of AD, (5, 6), and A peptides have remained the focus of the vast majority of studies in this research area.However, it is becoming clear that the A plaques or increased A load per se are unlikely to be the sole cause of AD, because a significant proportion of people without dementia have A deposits and clearance of A plaques by active immunization produced no clinical benefits (7). Also, the loss of synapses and the presence of phospho-tau in tangles seem to be better correlated with disease severity than A load (8). Moreover, the neurological deficits can be dissociated from A load in several mouse models of AD (9, 10) as well as human AD (7) and the clinical drug trials aimed at reducing A load (flurbiprofen) or its aggregation (tramiprosate) have yielded disappointing results. Although many factors could have influenced the failed drug trials and could be responsible for the discordant results in animal studies, the combined weight of these findings suggests that factors independent of A also contribute to AD pathogenesis (11,12). Recently, soluble aggregates of A peptides have been proposed to be the toxic agent (13). However, the molecular nature of such soluble aggregates is uncertain and their existence and precise composition remains debated (14, 15).The p...